Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Aniline Compounds"" wg kryterium: Temat


Tytuł :
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results.
Autorzy :
Heuser M; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany. .
Palmisiano N; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Mantzaris I; Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Mims A; Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
DiNardo C; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Silverman LR; Tisch Cancer Institute, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Wang ES; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Fiedler W; Department of Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Baldus C; Division of Hematology and Oncology, Charité University Hospital Berlin, Berlin, Germany.
Schwind S; Division of Hematology and Oncology, University Hospital Leipzig, Leipzig, Germany.
Pardee T; Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, NC, USA.
Perl AE; Division of Hematology-Oncology, Perelman School of Medicine, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA.
Cai C; Pharmaceuticals Division, Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA.
Kaulfuss S; Pharmaceuticals Division, Bayer AG, Berlin, Germany.
Lagkadinou E; Pharmaceuticals Division, Bayer AG, Berlin, Germany.
Rentzsch C; Pharmaceuticals Division, Bayer AG, Berlin, Germany.
Wagner M; Pharmaceuticals Division, Bayer AG, Berlin, Germany.
Wilkinson G; Pharmaceuticals Division, Bayer AG, Berlin, Germany.
Wu B; Pharmaceuticals Division, Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA.
Jeffers M; Pharmaceuticals Division, Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA.
Genvresse I; Pharmaceuticals Division, Bayer AG, Berlin, Germany.
Krämer A; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2020 Nov; Vol. 34 (11), pp. 2903-2913. Date of Electronic Publication: 2020 Jul 30.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Molecular Targeted Therapy*
Mutation*
Aniline Compounds/*therapeutic use
Antineoplastic Agents/*therapeutic use
Benzimidazoles/*therapeutic use
Enzyme Inhibitors/*therapeutic use
Isocitrate Dehydrogenase/*antagonists & inhibitors
Isocitrate Dehydrogenase/*genetics
Leukemia, Myeloid, Acute/*drug therapy
Leukemia, Myeloid, Acute/*genetics
Adult ; Aged ; Aniline Compounds/administration & dosage ; Aniline Compounds/adverse effects ; Aniline Compounds/pharmacokinetics ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacokinetics ; Benzimidazoles/administration & dosage ; Benzimidazoles/adverse effects ; Benzimidazoles/pharmacokinetics ; Bone Marrow/pathology ; DNA Mutational Analysis ; Enzyme Inhibitors/administration & dosage ; Enzyme Inhibitors/adverse effects ; Enzyme Inhibitors/pharmacokinetics ; Female ; Humans ; Isocitrate Dehydrogenase/metabolism ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/mortality ; Male ; Middle Aged ; Prognosis ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Integration of cancer and non-cancer human health risk assessment for Aniline enriched groundwater: a fuzzy inference system-based approach.
Autorzy :
Mohanta VL; Department of Environmental Science and Engineering, Indian Institute of Technology (Indian School of Mines), Dhanbad, 826004, India.
Mishra BK; Department of Environmental Science and Engineering, Indian Institute of Technology (Indian School of Mines), Dhanbad, 826004, India. .
Pokaż więcej
Źródło :
Environmental geochemistry and health [Environ Geochem Health] 2020 Nov; Vol. 42 (11), pp. 3623-3639. Date of Electronic Publication: 2020 May 18.
Typ publikacji :
Journal Article
MeSH Terms :
Aniline Compounds/*toxicity
Carcinogens, Environmental/*toxicity
Groundwater/*analysis
Risk Assessment/*methods
Water Pollutants, Chemical/*toxicity
Aniline Compounds/analysis ; Artificial Intelligence ; Carcinogens, Environmental/analysis ; Child ; Coal ; Environmental Exposure ; Environmental Monitoring/methods ; Fuzzy Logic ; Groundwater/chemistry ; Humans ; Hydrogen-Ion Concentration ; India ; Water Pollutants, Chemical/analysis
Czasopismo naukowe
Tytuł :
Identification of 4-anilino-6-aminoquinazoline derivatives as potential MERS-CoV inhibitors.
Autorzy :
Lee JY; Center for Convergent Research of Emerging Virus Infection (CEVI), Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, South Korea.
Shin YS; Center for Convergent Research of Emerging Virus Infection (CEVI), Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, South Korea.
Lee J; Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam-si, Gyeonggi-do 13488, South Korea.
Kwon S; Center for Convergent Research of Emerging Virus Infection (CEVI), Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, South Korea; Herbal Medicine Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, South Korea.
Jin YH; Center for Convergent Research of Emerging Virus Infection (CEVI), Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, South Korea; KM Application Center, Korea Institute of Oriental Medicine, Dong-gu, Daegu 41062, South Korea.
Jang MS; Center for Convergent Research of Emerging Virus Infection (CEVI), Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, South Korea; Department of Non-Clinical Studies, Korea Institute of Toxicology, Yuseong-gu, Daejeon 34114, South Korea.
Kim S; Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam-si, Gyeonggi-do 13488, South Korea.
Song JH; Center for Convergent Research of Emerging Virus Infection (CEVI), Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, South Korea.
Kim HR; Center for Convergent Research of Emerging Virus Infection (CEVI), Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, South Korea.
Park CM; Center for Convergent Research of Emerging Virus Infection (CEVI), Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, South Korea. Electronic address: .
Pokaż więcej
Źródło :
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2020 Oct 15; Vol. 30 (20), pp. 127472. Date of Electronic Publication: 2020 Aug 08.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Aniline Compounds/*pharmacology
Antiviral Agents/*pharmacology
Middle East Respiratory Syndrome Coronavirus/*drug effects
Quinazolines/*pharmacology
Aniline Compounds/chemical synthesis ; Aniline Compounds/pharmacokinetics ; Aniline Compounds/toxicity ; Animals ; Antiviral Agents/chemical synthesis ; Antiviral Agents/pharmacokinetics ; Antiviral Agents/toxicity ; Cell Line ; Chlorocebus aethiops ; Cricetulus ; Humans ; Mice ; Microbial Sensitivity Tests ; Molecular Structure ; Quinazolines/chemical synthesis ; Quinazolines/pharmacokinetics ; Quinazolines/toxicity ; Rats ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
Osimertinib in Resected EGFR -Mutated Non-Small-Cell Lung Cancer.
Autorzy :
Wu YL; From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).
Tsuboi M; From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).
He J; From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).
John T; From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).
Grohe C; From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).
Majem M; From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).
Goldman JW; From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).
Laktionov K; From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).
Kim SW; From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).
Kato T; From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).
Vu HV; From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).
Lu S; From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).
Lee KY; From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).
Akewanlop C; From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).
Yu CJ; From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).
de Marinis F; From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).
Bonanno L; From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).
Domine M; From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).
Shepherd FA; From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).
Zeng L; From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).
Hodge R; From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).
Atasoy A; From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).
Rukazenkov Y; From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).
Herbst RS; From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).
Pokaż więcej
Corporate Authors :
ADAURA Investigators
Źródło :
The New England journal of medicine [N Engl J Med] 2020 Oct 29; Vol. 383 (18), pp. 1711-1723. Date of Electronic Publication: 2020 Sep 19.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Acrylamides/*therapeutic use
Aniline Compounds/*therapeutic use
Antineoplastic Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
ErbB Receptors/*genetics
Lung Neoplasms/*drug therapy
Acrylamides/adverse effects ; Adult ; Aged ; Aged, 80 and over ; Aniline Compounds/adverse effects ; Antineoplastic Agents/adverse effects ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/surgery ; Chemotherapy, Adjuvant ; Disease-Free Survival ; Double-Blind Method ; Female ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/mortality ; Lung Neoplasms/surgery ; Lymphatic Metastasis ; Male ; Middle Aged ; Mutation ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Pneumonectomy ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł :
18F-Florbetapir PET in Primary Cerebral Amyloidoma.
Autorzy :
Soffers F; From the Department of Nuclear Medicine, University Hospital of Antwerp.
Ceyssens S; From the Department of Nuclear Medicine, University Hospital of Antwerp.
Buffet W; Departments of Pathology.
de Surgeloose D; Radiology.
Crols R; Neurology, Hospital Network Antwerp (ZNA), Antwerp, Belgium.
Pokaż więcej
Źródło :
Clinical nuclear medicine [Clin Nucl Med] 2020 Oct; Vol. 45 (10), pp. 838-839.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Aniline Compounds*
Ethylene Glycols*
Positron Emission Tomography Computed Tomography*
Amyloidosis/*diagnostic imaging
Aged ; Amyloidosis/pathology ; Biopsy ; Female ; Humans ; Magnetic Resonance Imaging ; Male ; Middle Aged ; White Matter/diagnostic imaging ; White Matter/pathology
Czasopismo naukowe
Tytuł :
Osimertinib induced cardiomyopathy: A case report.
Autorzy :
Shinomiya S; Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama University Hospital, 1397-1 Yamane, Hidaka-City, Saitama, Japan.
Kaira K
Yamaguchi O
Ishikawa K
Kagamu H
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 Sep 25; Vol. 99 (39), pp. e22301.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Acrylamides/*adverse effects
Aniline Compounds/*adverse effects
Cardiomyopathies/*chemically induced
Protein Kinase Inhibitors/*adverse effects
Acrylamides/therapeutic use ; Adenocarcinoma of Lung/drug therapy ; Adrenergic beta-Antagonists/therapeutic use ; Afatinib/therapeutic use ; Aged ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Aniline Compounds/therapeutic use ; Cardiomyopathies/drug therapy ; Cardiomyopathies/physiopathology ; Carvedilol/therapeutic use ; Diuretics/therapeutic use ; Enalapril/therapeutic use ; Female ; Furosemide/therapeutic use ; Humans ; Lung Neoplasms/pathology ; Protein Kinase Inhibitors/therapeutic use ; Recurrence ; Treatment Outcome ; Withholding Treatment
Czasopismo naukowe
Tytuł :
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.
Autorzy :
Wang R; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yamada T; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan. .; Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. .
Kita K; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Taniguchi H; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.; Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Arai S; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Fukuda K; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.; Nano Life Science Institute, Kanazawa University, Kanazawa, Japan.
Terashima M; Division of Functional Genomics, Cancer Research Institute, Kanazawa University Kanazawa, Kanazawa, Japan.
Ishimura A; Division of Functional Genomics, Cancer Research Institute, Kanazawa University Kanazawa, Kanazawa, Japan.
Nishiyama A; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Tanimoto A; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Takeuchi S; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.; Nano Life Science Institute, Kanazawa University, Kanazawa, Japan.
Ohtsubo K; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Yamashita K; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Yamano T; Department of Immunology, Graduate School of Medicine, Kanazawa University, Kanazawa, Japan.
Yoshimura A; Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Takayama K; Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Kaira K; Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Japan.
Taniguchi Y; Department of Thoracic Oncology, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Japan.
Atagi S; Department of Thoracic Oncology, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Japan.
Uehara H; Division of Pathology, Tokushima University Hospital, Tokushima, Japan.
Hanayama R; Nano Life Science Institute, Kanazawa University, Kanazawa, Japan.; Department of Immunology, Graduate School of Medicine, Kanazawa University, Kanazawa, Japan.
Matsumoto I; Department of Thoracic, Cardiovascular and General Surgery, Kanazawa University, Kanazawa, Japan.
Han X; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.; Nano Life Science Institute, Kanazawa University, Kanazawa, Japan.; Division of Tumor Dynamics and Regulation, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Matsumoto K; Nano Life Science Institute, Kanazawa University, Kanazawa, Japan.; Division of Tumor Dynamics and Regulation, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.; Tumor Microenvironment Research Unit, Institute for Frontier Science Initiative, Kanazawa University, Kanazawa, Japan.
Wang W; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China. .
Suzuki T; Division of Functional Genomics, Cancer Research Institute, Kanazawa University Kanazawa, Kanazawa, Japan.; Tumor Microenvironment Research Unit, Institute for Frontier Science Initiative, Kanazawa University, Kanazawa, Japan.
Yano S; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan. .; Nano Life Science Institute, Kanazawa University, Kanazawa, Japan. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2020 Sep 14; Vol. 11 (1), pp. 4607. Date of Electronic Publication: 2020 Sep 14.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Acrylamides/*therapeutic use
Aniline Compounds/*therapeutic use
Lung Neoplasms/*drug therapy
Lung Neoplasms/*genetics
Mutation/*genetics
Proto-Oncogene Proteins/*metabolism
Receptor Protein-Tyrosine Kinases/*metabolism
Receptor, IGF Type 1/*antagonists & inhibitors
Acrylamides/pharmacology ; Aged, 80 and over ; Aniline Compounds/pharmacology ; Animals ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Cell Line, Tumor ; Cell Survival/drug effects ; ErbB Receptors/genetics ; Gene Expression Regulation, Neoplastic/drug effects ; Hepatocyte Nuclear Factor 3-alpha/metabolism ; Humans ; Imidazoles/pharmacology ; Lung Neoplasms/pathology ; Male ; Mice ; Models, Biological ; Phosphorylation/drug effects ; Pyrazines/pharmacology ; RNA, Messenger/genetics ; RNA, Messenger/metabolism ; Receptor, IGF Type 1/genetics ; Receptor, IGF Type 1/metabolism ; Up-Regulation/drug effects
Czasopismo naukowe
Tytuł :
The efficacy and safety of osimertinib in treating nonsmall cell lung cancer: A PRISMA-compliant systematic review and meta-analysis.
Autorzy :
Liu J; Clinics of Cadre, Department of Outpatient, First Medical Center of Chinese PLA General Hospital, Beijing, China.
Li X
Shao Y
Guo X
He J
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 Aug 21; Vol. 99 (34), pp. e21826.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Acrylamides/*therapeutic use
Aniline Compounds/*therapeutic use
Antineoplastic Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Acrylamides/adverse effects ; Aniline Compounds/adverse effects ; Antineoplastic Agents/adverse effects ; Carcinoma, Non-Small-Cell Lung/genetics ; Cigarette Smoking ; ErbB Receptors/genetics ; Humans ; Lung Neoplasms/genetics ; Mutation ; Pneumonia/chemically induced ; Progression-Free Survival ; Survival Rate
Czasopismo naukowe
Tytuł :
Structural Basis of AZD9291 Selectivity for EGFR T790M.
Autorzy :
Yan XE
Ayaz P; D. E. Shaw Research, New York, New York 10036, United States.
Zhu SJ; Institute of Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao 266021, China.
Zhao P
Liang L
Zhang CH; D. E. Shaw Research, New York, New York 10036, United States.
Wu YC
Li JL; D. E. Shaw Research, New York, New York 10036, United States.
Choi HG; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, United States.
Huang X; Hongyun Biotech Co., Ltd., Nanjing, Jiangsu 211112, China.
Shan Y; D. E. Shaw Research, New York, New York 10036, United States.
Shaw DE; D. E. Shaw Research, New York, New York 10036, United States.; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, New York 10032, United States.
Yun CH
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2020 Aug 13; Vol. 63 (15), pp. 8502-8511. Date of Electronic Publication: 2020 Aug 03.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Acrylamides/*pharmacology
Aniline Compounds/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Acrylamides/chemistry ; Aniline Compounds/chemistry ; Crystallography, X-Ray ; ErbB Receptors/chemistry ; ErbB Receptors/genetics ; ErbB Receptors/metabolism ; Humans ; Molecular Docking Simulation ; Molecular Dynamics Simulation ; Point Mutation ; Protein Conformation/drug effects ; Protein Kinase Inhibitors/chemistry
Czasopismo naukowe
Tytuł :
Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan.
Autorzy :
Ohe Y; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Kato T; Department of Thoracic Oncology, Kanagawa Cancer Center, Kanagawa, Japan.
Sakai F; Department of Diagnostic Radiology, Saitama Medical University International Medical Center, Saitama, Japan.
Kusumoto M; Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan.
Endo M; Division of Diagnostic Radiology, Shizuoka Cancer Center, Shizuoka, Japan.
Saito Y; Department of Pulmonary Medicine and Oncology, Nippon Medical School, Tokyo, Japan.
Baba T; Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Japan.
Sata M; Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University, Tochigi, Japan.
Yamaguchi O; Department of Respiratory Medicine, Saitama Medical University International Medical Center, Saitama, Japan.
Sakamoto K; Research & Development, AstraZeneca K.K., Osaka, Japan.
Sugeno M; Research & Development, AstraZeneca K.K., Osaka, Japan.
Tamura R; Research & Development, AstraZeneca K.K., Osaka, Japan.
Tokimoto T; Research & Development, AstraZeneca K.K., Osaka, Japan.
Shimizu W; Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan.
Gemma A; Department of Pulmonary Medicine and Oncology, Nippon Medical School, Tokyo, Japan.
Pokaż więcej
Źródło :
Japanese journal of clinical oncology [Jpn J Clin Oncol] 2020 Aug 04; Vol. 50 (8), pp. 909-919.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
Acrylamides/*therapeutic use
Aniline Compounds/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Carcinoma, Non-Small-Cell Lung/*genetics
Lung Neoplasms/*drug therapy
Lung Neoplasms/*genetics
Mutation/*genetics
Acrylamides/adverse effects ; Aged ; Aniline Compounds/adverse effects ; ErbB Receptors/genetics ; Female ; Humans ; Japan ; Male ; Progression-Free Survival ; Protein Kinase Inhibitors/therapeutic use ; Survival Rate ; Treatment Outcome
Czasopismo naukowe
Tytuł :
A photochemical dehydrogenative strategy for aniline synthesis.
Autorzy :
U Dighe S; Department of Chemistry, University of Manchester, Manchester, UK.
Juliá F; Department of Chemistry, University of Manchester, Manchester, UK.
Luridiana A; Department of Chemistry, University of Manchester, Manchester, UK.
Douglas JJ; Early Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, UK.
Leonori D; Department of Chemistry, University of Manchester, Manchester, UK. .
Pokaż więcej
Źródło :
Nature [Nature] 2020 Aug; Vol. 584 (7819), pp. 75-81. Date of Electronic Publication: 2020 Aug 05.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Photochemical Processes*/radiation effects
Aniline Compounds/*chemical synthesis
Hydrogen/*chemistry
Amination ; Amines/chemistry ; Aniline Compounds/chemistry ; Biological Products/chemical synthesis ; Biological Products/chemistry ; Catalysis/radiation effects ; Cyclohexanones/chemistry ; Oxidation-Reduction/radiation effects ; Steroids/chemical synthesis ; Steroids/chemistry ; Terpenes/chemical synthesis ; Terpenes/chemistry
Czasopismo naukowe
Tytuł :
Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor.
Autorzy :
Ando T; Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan. .
Sano H; Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
Yokoo M; Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
Kusaba K; Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
Kidoguchi K; Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
Yamaguchi K; Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
Katsuya H; Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
Yoshihara S; Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.
Kubota Y; Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.; Department of Transfusion Medicine, Saga University Hospital, Saga, Japan.
Kojima K; Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.; Department of Hematology, Kochi Medical School, Kochi University, Kochi, Japan.
Kimura S; Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
Pokaż więcej
Źródło :
International journal of hematology [Int J Hematol] 2020 Aug; Vol. 112 (2), pp. 249-253. Date of Electronic Publication: 2020 Mar 17.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Recurrence*
Tissue Donors*
Aniline Compounds/*administration & dosage
Hematopoietic Stem Cell Transplantation/*methods
Leukemia, Myeloid, Acute/*genetics
Leukemia, Myeloid, Acute/*surgery
Pyrazines/*administration & dosage
Tandem Repeat Sequences/*genetics
fms-Like Tyrosine Kinase 3/*genetics
Aniline Compounds/pharmacology ; Female ; Graft vs Leukemia Effect/drug effects ; Humans ; Leukemia, Myeloid, Acute/immunology ; Mutation ; Pyrazines/pharmacology ; Remission Induction ; Reoperation ; Treatment Outcome ; fms-Like Tyrosine Kinase 3/antagonists & inhibitors
Czasopismo naukowe
Tytuł :
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.
Autorzy :
Hochhaus A; Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany. .
Gambacorti-Passerini C; University of Milano-Bicocca, Monza, Italy.
Abboud C; Washington University School of Medicine, St. Louis, MO, USA.
Gjertsen BT; Haukeland University Hospital, Helse Bergen, and University of Bergen, Bergen, Norway.
Brümmendorf TH; Universitätsklinikum RWTH Aachen, Aachen, Germany.
Smith BD; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Ernst T; Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.
Giraldo-Castellano P; CIBER Enfermedades Raras, Miguel Servet University Hospital, Zaragoza, Spain.
Olsson-Strömberg U; University of Uppsala and Department of Hematology, University Hospital, Uppsala, Sweden.
Saussele S; Universitätsmedizin Mannheim, Heidelberg University, Mannheim, Germany.
Bardy-Bouxin N; Pfizer International Operation-Oncology, Paris, France.
Viqueira A; Pfizer SLU, Madrid, Spain.
Leip E; Pfizer Inc, Cambridge, MA, USA.
Russell-Smith TA; Pfizer Inc, New York, NY, USA.
Leone J; Pfizer Inc, Cambridge, MA, USA.
Rosti G; University Hospital, University of Bologna, Bologna, Italy.
Watts J; University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA.
Giles FJ; Developmental Therapeutics Consortium, Chicago, IL, USA.
Pokaż więcej
Corporate Authors :
BYOND Study Investigators
Źródło :
Leukemia [Leukemia] 2020 Aug; Vol. 34 (8), pp. 2125-2137. Date of Electronic Publication: 2020 Jun 22.
Typ publikacji :
Clinical Trial, Phase IV; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Aniline Compounds/*therapeutic use
Leukemia, Myeloid, Chronic-Phase/*drug therapy
Nitriles/*therapeutic use
Quinolines/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Aniline Compounds/adverse effects ; Female ; Humans ; Leukemia, Myeloid, Chronic-Phase/genetics ; Leukemia, Myeloid, Chronic-Phase/psychology ; Male ; Middle Aged ; Nitriles/adverse effects ; Philadelphia Chromosome ; Protein Kinase Inhibitors/therapeutic use ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Quality of Life ; Quinolines/adverse effects
Czasopismo naukowe
Tytuł :
Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.
Autorzy :
Li XF; Department of Oncology and Hematology, The Second Hospital of Jilin University, 218 Ziqiang Street, Nanguan District, Changchun, 130041, Jilin, People's Republic of China.
Shen WZ; Department of Oncology and Hematology, The Second Hospital of Jilin University, 218 Ziqiang Street, Nanguan District, Changchun, 130041, Jilin, People's Republic of China.
Jin X; Department of Oncology and Hematology, The Second Hospital of Jilin University, 218 Ziqiang Street, Nanguan District, Changchun, 130041, Jilin, People's Republic of China.
Ren P; Department of Thoracic Surgery, The First Hospital of Jilin University, Chaoyang, Changchun, 130021, Jilin, People's Republic of China. .
Zhang J; Department of Respiratory Medicine, The Second Hospital of Jilin University, 218 Ziqiang Street, Nanguan District, Changchun, 130041, Jilin, People's Republic of China. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Jul 08; Vol. 10 (1), pp. 11236. Date of Electronic Publication: 2020 Jul 08.
Typ publikacji :
Journal Article
MeSH Terms :
Acrylamides/*pharmacology
Aniline Compounds/*pharmacology
Carcinoma, Non-Small-Cell Lung/*drug therapy
Drug Resistance, Neoplasm/*genetics
Lung Neoplasms/*drug therapy
MicroRNAs/*metabolism
Protein Kinase Inhibitors/*pharmacology
Acrylamides/therapeutic use ; Aniline Compounds/therapeutic use ; Animals ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Proliferation/genetics ; Down-Regulation/drug effects ; Epithelial-Mesenchymal Transition/drug effects ; Epithelial-Mesenchymal Transition/genetics ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/genetics ; Gene Expression Regulation, Neoplastic ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Male ; Mice ; MicroRNAs/agonists ; MicroRNAs/antagonists & inhibitors ; Mutation ; Neoplasm Invasiveness/genetics ; Protein Kinase Inhibitors/therapeutic use ; Transcription Factor 4/genetics ; Wnt1 Protein/genetics ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Glycogen synthase kinase-3 inhibition overcomes epithelial-mesenchymal transition-associated resistance to osimertinib in EGFR-mutant lung cancer.
Autorzy :
Fukuda K; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.; Nano Life Science Institute, Kanazawa University, Kanazawa, Japan.
Takeuchi S; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.; Nano Life Science Institute, Kanazawa University, Kanazawa, Japan.
Arai S; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Kita K; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Tanimoto A; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Nishiyama A; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Yano S; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.; Nano Life Science Institute, Kanazawa University, Kanazawa, Japan.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2020 Jul; Vol. 111 (7), pp. 2374-2384. Date of Electronic Publication: 2020 Jun 11.
Typ publikacji :
Journal Article
MeSH Terms :
Mutation*
Acrylamides/*pharmacology
Aniline Compounds/*pharmacology
Drug Resistance, Neoplasm/*genetics
Epithelial-Mesenchymal Transition/*drug effects
Epithelial-Mesenchymal Transition/*genetics
Glycogen Synthase Kinase 3/*antagonists & inhibitors
Protein Kinase Inhibitors/*pharmacology
Acrylamides/therapeutic use ; Aniline Compounds/therapeutic use ; Apoptosis ; Cell Line, Tumor ; Cell Survival/drug effects ; Dose-Response Relationship, Drug ; ErbB Receptors/genetics ; Gene Expression Profiling ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; MicroRNAs/genetics ; Models, Biological ; Protein Kinase Inhibitors/therapeutic use ; Proto-Oncogene Proteins c-akt ; Signal Transduction/drug effects
Czasopismo naukowe
Tytuł :
PANI/PbS QD nanocomposite structure for visible light driven photocatalytic degradation of rhodamine 6G.
Autorzy :
Chhabra VA; Centre for Development of Advanced Computing (C-DAC), Phase VIII, Mohali, 160071, India.
Kaur R; Department of Physics, Panjab University, Sector 14, Chandigarh, 160014, India.
Walia MS; Central Scientific Instruments Organization (CSIR-CSIO), Sector 30 C, Chandigarh, 160030, India.
Kim KH; Department of Civil and Environmental Engineering, Hanyang University, 222 Wangsimni-Ro, Seoul, 04763, Republic of Korea. Electronic address: .
Deep A; Central Scientific Instruments Organization (CSIR-CSIO), Sector 30 C, Chandigarh, 160030, India.
Pokaż więcej
Źródło :
Environmental research [Environ Res] 2020 Jul; Vol. 186, pp. 109615. Date of Electronic Publication: 2020 Apr 29.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Aniline Compounds*
Nanocomposites*
Light ; Photolysis ; Rhodamines
Czasopismo naukowe
Tytuł :
Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia.
Autorzy :
Hino M; Department of Hematology, Osaka City University Hospital, 1-4-3, Asahi-machi, Abeno-ku, Osaka, Japan. .
Matsumura I; Kindai University Hospital, Osaka, Japan.
Fujisawa S; Yokohama City University Medical Center, Yokohama, Japan.
Ishizawa K; Yamagata University Hospital, Yamagata, Japan.
Ono T; Hamamatsu University Hospital, Shizuoka, Japan.
Sakaida E; Chiba University Hospital, Chiba, Japan.
Sekiguchi N; National Hospital Organization Disaster Medical Center, Tokyo, Japan.
Tanetsugu Y; Pfizer R&D Japan GK, Tokyo, Japan.
Fukuhara K; Pfizer R&D Japan GK, Tokyo, Japan.
Ohkura M; Pfizer R&D Japan GK, Tokyo, Japan.
Koide Y; Pfizer R&D Japan GK, Tokyo, Japan.
Takahashi N; Akita University Hospital, Akita, Japan.
Pokaż więcej
Źródło :
International journal of hematology [Int J Hematol] 2020 Jul; Vol. 112 (1), pp. 24-32. Date of Electronic Publication: 2020 Apr 11.
Typ publikacji :
Clinical Trial, Phase II; Journal Article
MeSH Terms :
Aniline Compounds/*administration & dosage
Leukemia, Myeloid, Chronic-Phase/*drug therapy
Leukemia, Myeloid, Chronic-Phase/*genetics
Nitriles/*administration & dosage
Quinolines/*administration & dosage
Adult ; Aged ; Aged, 80 and over ; Alanine Transaminase/blood ; Aniline Compounds/adverse effects ; Asian Continental Ancestry Group ; Aspartate Aminotransferases/blood ; Diarrhea ; Female ; Follow-Up Studies ; Humans ; Leukemia, Myeloid, Chronic-Phase/pathology ; Male ; Middle Aged ; Nitriles/adverse effects ; Philadelphia Chromosome ; Quinolines/adverse effects ; Transcription, Genetic ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Comparative catalytic degradation of a metabolite 3,5-dichloroaniline derived from dicarboximide fungicide by laccase and MnO 2 mediators.
Autorzy :
Sarker A; School of Applied Biosciences, Collage of Agriculture and Life Sciences, Kyungpook National University, Daegu, 41566, Republic of Korea.
Lee SH; School of Applied Biosciences, Collage of Agriculture and Life Sciences, Kyungpook National University, Daegu, 41566, Republic of Korea.
Kwak SY; School of Applied Biosciences, Collage of Agriculture and Life Sciences, Kyungpook National University, Daegu, 41566, Republic of Korea.
Nandi R; School of Applied Biosciences, Collage of Agriculture and Life Sciences, Kyungpook National University, Daegu, 41566, Republic of Korea.
Kim JE; School of Applied Biosciences, Collage of Agriculture and Life Sciences, Kyungpook National University, Daegu, 41566, Republic of Korea. Electronic address: .
Pokaż więcej
Źródło :
Ecotoxicology and environmental safety [Ecotoxicol Environ Saf] 2020 Jun 15; Vol. 196, pp. 110561. Date of Electronic Publication: 2020 Apr 08.
Typ publikacji :
Journal Article
MeSH Terms :
Aniline Compounds/*analysis
Fungicides, Industrial/*analysis
Laccase/*metabolism
Manganese Compounds/*chemistry
Oxides/*chemistry
Trametes/*enzymology
Aniline Compounds/metabolism ; Benzaldehydes/chemistry ; Catalysis ; Catechols/chemistry ; Fungicides, Industrial/metabolism ; Phenols/chemistry
Czasopismo naukowe
Tytuł :
Development of a sensitive electrochemical immunosensor using polyaniline functionalized graphene quantum dots for detecting a depression marker.
Autorzy :
Sun B; School of Pharmacy, Lanzhou University, Lanzhou 730000, China.
Wang Y; School of Pharmacy, Lanzhou University, Lanzhou 730000, China.
Li D; School of Pharmacy, Lanzhou University, Lanzhou 730000, China.
Li W; Center for Inflammation, Translational and Clinical Lung Research, Temple University School of Medicine, Philadelphia, PA, USA.
Gou X; School of Chemistry and Chemical Engineering, Nanjing University, 210046, China.
Gou Y; Center for Disease Prevention and Control in Northwest Theater of the Chinese People's Liberation Army, Lanzhou 730000, China.
Hu F; School of Pharmacy, Lanzhou University, Lanzhou 730000, China. Electronic address: .
Pokaż więcej
Źródło :
Materials science & engineering. C, Materials for biological applications [Mater Sci Eng C Mater Biol Appl] 2020 Jun; Vol. 111, pp. 110797. Date of Electronic Publication: 2020 Mar 02.
Typ publikacji :
Journal Article
MeSH Terms :
Aniline Compounds/*chemistry
Biomarkers/*analysis
Biosensing Techniques/*instrumentation
Depression/*diagnosis
Electrochemical Techniques/*instrumentation
Graphite/*chemistry
Quantum Dots/*chemistry
Adult ; Aniline Compounds/chemical synthesis ; Biomarkers/blood ; Carbon/chemistry ; Depression/blood ; Dielectric Spectroscopy ; Electrodes ; Glass/chemistry ; Graphite/chemical synthesis ; Humans ; Reproducibility of Results
Czasopismo naukowe
Tytuł :
No evidence for amyloid pathology as a key mediator of neurodegeneration post-stroke - a seven-year follow-up study.
Autorzy :
Hagberg G; Bærum Hospital, Vestre Viken Hospital Trust, N-3004, Drammen, Norway. .; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. .
Ihle-Hansen H; Bærum Hospital, Vestre Viken Hospital Trust, N-3004, Drammen, Norway.; Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway.
Fure B; Department of Neurology, Department of Internal Medicine, Central Hospital Karlstad and Faculty of Medicine, Örebro University, Örebro, Sweden.
Thommessen B; Department of Neurology, Akershus University Hospital, Oslo, Norway.
Ihle-Hansen H; Bærum Hospital, Vestre Viken Hospital Trust, N-3004, Drammen, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Øksengård AR; Bærum Hospital, Vestre Viken Hospital Trust, N-3004, Drammen, Norway.
Beyer MK; Division of Radiology, Nuclear Medicine Oslo University Hospital, Oslo, Norway.
Wyller TB; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway.
Müller EG; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Pendlebury ST; Centre for Prevention of Stroke and Dementia, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.; NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK.
Selnes P; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Neurology, Akershus University Hospital, Oslo, Norway.
Pokaż więcej
Źródło :
BMC neurology [BMC Neurol] 2020 May 08; Vol. 20 (1), pp. 174. Date of Electronic Publication: 2020 May 08.
Typ publikacji :
Journal Article
MeSH Terms :
Aniline Compounds*
Benzothiazoles*
Positron-Emission Tomography*
Amyloid/*metabolism
Cognitive Dysfunction/*etiology
Stroke/*complications
Aged ; Aged, 80 and over ; Amyloid beta-Peptides/cerebrospinal fluid ; Amyloidosis ; Atrophy/complications ; Biomarkers/cerebrospinal fluid ; Cognitive Dysfunction/metabolism ; Cohort Studies ; Dementia/complications ; Female ; Follow-Up Studies ; Humans ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Stroke/diagnostic imaging ; Stroke/metabolism
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies